NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.

Journal Article (Journal Article)

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

Full Text

Duke Authors

Cited Authors

  • Schaeffer, E; Srinivas, S; Antonarakis, ES; Armstrong, AJ; Bekelman, JE; Cheng, H; D'Amico, AV; Davis, BJ; Desai, N; Dorff, T; Eastham, JA; Farrington, TA; Gao, X; Horwitz, EM; Ippolito, JE; Kuettel, MR; Lang, JM; McKay, R; McKenney, J; Netto, G; Penson, DF; Pow-Sang, JM; Reiter, R; Richey, S; Roach Iii, M; Rosenfeld, S; Shabsigh, A; Spratt, DE; Teply, BA; Tward, J; Shead, DA; Freedman-Cass, DA

Published Date

  • February 2, 2021

Published In

Volume / Issue

  • 19 / 2

Start / End Page

  • 134 - 143

PubMed ID

  • 33545689

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2021.0008


  • eng

Conference Location

  • United States